Juli 25, 2021: Kite, een Gilead Company (Nasdaq: GILD), heeft vandaag aangekondigd dat de FDA TecartusTM (brexucabtagene autoleucel, voorheen KTE-X19), de eerste en enige goedgekeurde chimere antigeenreceptor CAR T-celtherapie for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, accelerated approval (MCL). The FDA granted priority review and breakthrough therapy designation to this one-time therapy, which was based on the results of ZUMA-2, a single-arm, open-label study in which 87 percent of patients responded to a single infusion of Tecartus, with 62 percent achieving a complete response (CR). 18% of patients who were evaluated for safety had cytokine-afgiftesyndroom (CRS) of Grade 3 or higher, and 37% had neurologic toxicities of Grade 3 or higher.
“Despite promising advances, there are still significant gaps in treatment for MCL patients who progress after initial therapy,” said Michael Wang, MD, ZUMA-2 Lead Investigator and Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center. “Many patients have high-risk disease, which means they are more likely to progress despite treatment. “Tecartus is the first cell therapy available to people with relapsed or refractory MCL. It has an impressive response rate of nearly 90% and early clinical evidence suggests that remissions may last through later lines of therapy. This makes it an important choice for these patients.”
“We zijn trots om onze tweede celtherapie te lanceren omdat Kite zich inzet om de belofte van CAR T-therapie to patients with haematological cancers,” said Christi Shaw, Kite’s Chief Executive Officer. “I would like to express my gratitude to the patient study participants, caregivers, clinical researchers, regulators, and dedicated Kite colleagues who contributed to this approval, and we look forward to working with the lymfoom community to bring this potentially transformative therapy to patients with relapsed or refractory MCL.”
Tecartus’ product label includes a boxed warning about the risks of CRS and neurologic toxicities. The FDA has approved a Risk Evaluation and Mitigation Strategy (REMS) for Tecartus, which has been combined with the REMS for Yescarta® (axicabtagene ciloleucel). The REMS programme will inform and educate healthcare professionals about the risks associated with Tecartus therapy, and training and certification in the REMS programme will be a requirement for centres offering Tecartus therapy to receive final authorization.
MCL is een zeldzaam type non-Hodgkin-lymfoom (NHL) die ontstaat uit cellen in de "mantelzone" van de lymfeklier en die voornamelijk mannen ouder dan 60 jaar treft. Na een terugval is MCL extreem agressief en veel patiënten gaan na de behandeling vooruit.
The Lymphoma Research Foundation’s Chief Executive Officer, Meghan Gutierrez, said, “This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease.” “Researchers have made significant progress in our understanding of this disease over the last decade, and we’ve seen an increase in patient clinical trials, which we hope will continue to improve treatment strategies and options for people with mantle cell lymphoma. Today’s news builds on that progress and gives mantelcel patients and their families reason to be hopeful.”
Kite’s commercial manufacturing facility in El Segundo, California, will produce Tecartus. Kite achieved a 96 percent manufacturing success rate in the ZUMA-2 trial, with a median manufacturing turnaround time of 15 days from leukapheresis to product delivery. Patients with advanced disease, who are severely ill and at risk of rapid progression, require manufacturing speed in particular.
Kite Konnect®, een geïntegreerd technologieplatform dat informatie en hulp biedt tijdens het therapieproces voor gecommercialiseerde Kite's CAR T-therapieën, including courier tracking for shipments and manufacturing status updates, is available to patients whose healthcare professionals have prescribed Tecartus therapy. Kite Konnect is a support system for patients who are receiving Yescarta or Tecartus, as well as information for the healthcare teams who are supporting them.
KTE-X19 wordt momenteel geëvalueerd in de Europese Unie en het Europees Geneesmiddelenbureau heeft het de aanduiding Priority Medicines (PRIME) toegekend voor recidiverende of refractaire MCL.
Resultaten van de Tecartus-proef
The approval of Tecartus is based on results from the ongoing ZUMA-2 pivotal trial, which is a single arm, open-label study. 74 adult patients with relapsed or refractory MCL who had previously received anthracycline- or bendamustine-containing chemotherapy, anti-CD20 antibody treatment, or a Bruton tyrosine kinase inhibitor were enrolled in the trial (ibrutinib or acalabrutinib). The primary endpoint was the objective response rate (ORR), which was defined as the combined rate of CR and partial responses as judged by an Independent Radiologic Review Committee according to the Lugano Classification (2014). (IRRC).
In het onderzoek reageerde 87 procent van de patiënten (n=60 evalueerbaar voor werkzaamheidsanalyse) op een enkele Tecartus-infusie, waarbij 62 procent een volledige respons bereikte. Follow-up was ten minste zes maanden na de eerste objectieve ziekterespons voor alle patiënten. De mediane reactietijd moet nog worden bepaald.
In the experiment, 18% of patients (n=82 evaluable for safety) had Grade 3 or higher CRS, while 37% of patients had neurologic problems. Anemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatremia, hypertension, infection-pathogen unclear, pneumonia, hypocalcemia, and lymphopenia were the most prevalent Grade 3 or higher adverse effects (10%). With a Risk Evaluation and Mitigation Strategy, the FDA approved Tecartus (REMS). The Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) REMS Program has been integrated with the Tecartus REMS and is now known as the “Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) REMS Program”
Over Tecartus
Tecartus is an autologous, anti-CD19 CAR T cell therapy. Tecartus uses the XLP™ fabricageproces dat T-celverrijking omvat, een noodzakelijke stap in bepaalde B-celmaligniteiten waarbij circulerende lymfoblasten een gemeenschappelijk kenmerk zijn. Naast MCL bevindt Tecartus zich momenteel ook in fase 1/2-onderzoeken bij acute lymfatische leukemie (ALL) en chronische lymfatische leukemie (CLL). The use of Tecartus in ALL and CLL is investigational, and its safety and efficacy have not been established in these cancer types.
Tecartus-indicatie
Tecartus is een op CD19 gerichte genetisch gemodificeerde autologe T-celimmunotherapie die geïndiceerd is voor de behandeling van volwassen patiënten met recidiverend of refractair mantelcellymfoom (MCL).
Deze indicatie is goedgekeurd onder versnelde goedkeuring op basis van het algehele responspercentage en de duurzaamheid van de respons. Voortgezette goedkeuring voor deze indicatie kan afhankelijk zijn van verificatie en beschrijving van het klinische voordeel in een bevestigend onderzoek.
